^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial

Published date:
05/26/2022
Excerpt:
The Short-HER study randomized 1254 patients with HER2+ early breast cancer to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with anthracycline-taxane chemotherapy. 853 patients with HR+ BC (ER and/or PgR >10%) were included…patients who received AI had a significantly better DFS as compared to patients who received TAM or TAM-AI: 7-yr DFS 87.3% vs 81.7%, log-rank P=0.017 (HR 1.46, 95%CI 1.05-2.03).
Secondary therapy:
Aromatase inhibitor; Chemotherapy
DOI:
10.1200/JCO.2022.40.16_suppl.547
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

Excerpt:
...- Estrogen receptor- and/or progesterone receptor-positive or negative tumor...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Neo- / adjuvant trial to compare two therapies for patients with high rist breast cancer. Patients will receive either dose-dense the combination EnPC or dose-dense and dose-tailored EC-D (GAIN-2). Neo- / adjuvante Studie zum Vergleich zweier Therapiearme bei Brustkrebs-Patientinnen mit erhöhtem Risiko. Patientinnen erhalten entweder dosisdicht die Kombination EnPC oder dosisdicht und dosisangepasst EC-D.

Excerpt:
...High risk breast cancer as defined as: • HER2 positive or triple-negative tumors irrespective of nodal status or • Luminal B-like tumors (ER and/or PgR positive, HER2 negative, Ki-67 > 20%) with involved lymph nodes or • 4 or more involved lymph nodes. ...
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Excerpt:
...- Estrogen receptor or progesterone receptor positive...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

Excerpt:
......
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Excerpt:
...- Estrogen receptor-positive and/or progesterone receptor-positive disease...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Excerpt:
...- Estrogen receptor and/or progesterone receptor positive...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Excerpt:
...- Estrogen receptor- and/or progesterone receptor-positive tumor...
Trial ID: